<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119780</url>
  </required_header>
  <id_info>
    <org_study_id>LG-HACL014</org_study_id>
    <nct_id>NCT02119780</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar Region</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      This study is purposed to evaluate the efficacy and safety of YVOIRE® contour compared with
      Restylane SubQ™ injected into the anteromedial malar region.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) score</measure>
    <time_frame>26 weeks after treatment</time_frame>
    <description>Mean of MFAS score as assessed by the independent blinded rater</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) score</measure>
    <time_frame>2, 14, and 52 weeks after treatment</time_frame>
    <description>Mean of MFAS score as assessed by the independent blinded rater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) score</measure>
    <time_frame>2, 14, 26, and 52 weeks after treatment</time_frame>
    <description>Changes of MFAS score as assessed by the independent blinded rater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid Face Aesthetic Scale (MFAS) Responder rate</measure>
    <time_frame>2, 14, 26, and 52 weeks after treatment</time_frame>
    <description>MFAS Responder (at least a one-point improvement on the MFAS) rate as assessed by the independent blinded rater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) score</measure>
    <time_frame>2, 14, 26, and 52 weeks after treatment</time_frame>
    <description>Mean of GAIS score as assessed by subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) Responder rate</measure>
    <time_frame>2, 14, 26, and 52 weeks after treatment</time_frame>
    <description>GAIS Responder (at least a one-point improvement on the GAIS) rate as assessed by subject</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Normal, Healthy Adults With Moderate, Severe, or Very Severe Volume Loss of Anteromedial Malar Region</condition>
  <arm_group>
    <arm_group_label>YVOIRE® contour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Restylane SubQ™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YVOIRE® contour</intervention_name>
    <description>YVOIRE® contour injection into the anteromedial malar region</description>
    <arm_group_label>YVOIRE® contour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Restylane SubQ™</intervention_name>
    <description>Restylane SubQ™ injection into the anteromedial malar region</description>
    <arm_group_label>Restylane SubQ™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male or female, 20-65 years of age

          -  Have anteromedial malar region volume loss as grade 2, 3, or 4 on the Mid Face
             Aesthetic Scale (MFAS) symmetrically on both sides

          -  Desire filler treatment to correct volume loss in the anteromedial malar region

          -  Accept the obligation not to receive any other mid facial procedures or treatments
             during the study

          -  Signed informed consent

          -  Those who fall under one of the following 3 cases

               1. Males or females who are surgically sterile

               2. Post-menopausal females who are above 45 years of age and 2 years after the last
                  menstruation

               3. Fertile premenopausal females or males without having a surgical sterilization,
                  who have agreed to use at least two contraception methods (one of the barrier
                  methods must be included) for up to 14 days after the last treatment of the
                  investigational device to avoid pregnancy

        Exclusion Criteria:

          -  Have a history of hypertrophic scars or keloids

          -  Other criteria as identified in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

